Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

UK Health Body Approves Novartis's Tasigna For CML

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/25/2012 | 01:16am CEST

The U.K.'s health-cost regulator has decided to back an expensive cancer drug from Novartis AG (NVS) for treating chronic myeloid leukemia--but not one from U.S.-based Bristol-Myers Squibb Co. (BMY)--after the Swiss drug maker offered to cut the drug's price.

The independent National Institute for Clinical Excellence, known by its acronym NICE, said Wednesday it approved Novartis's Tasigna and the company's older drug, whose brand name is Glivec, for use in treating CML on the publicly funded National Health Service. The generic names for Tasigna and Glivec are nilotinib and imatinib, respectively.

However, NICE said it wasn't approving Bristol-Myers Squibb's Sprycel, also known as dasatinib.

CML is a cancer of blood-forming cells in the bone marrow that usually develops slowly, which is why it is described as a chronic form of the disease.

NICE director Carole Longson said: "The recommendations reaffirm the use of imatinib as an effective treatment for the majority of patients and a cost-effective use of NHS resources, and we are also very pleased to be able to add a further treatment option for these patients by recommending nilotinib.

"Although no trials directly comparing dasatinib and nilotinib were available, the committee concluded from indirect comparisons that dasatinib and nilotinib could be considered equally as effective in treating CML.

"However, the manufacturer of nilotinib has already agreed with the Department of Health to provide the drug to the NHS at a discounted price. This reduction in cost enabled the independent committee to approve nilotinib for use on the NHS."

Dasatinib and nilotinib both cost over GBP30,000 per patient a year and the standard dose of imatinib costs GBP20,000.

NICE didn't disclose the price discount offered by Novartis for nilotinib.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS AG
02:21p NOVARTIS : expands global collaboration with Amgen to commercialize first-in-cla..
02:14pDJELI LILLY AND : Working to Cut Costs
01:31p NOVARTIS : Sandoz proposed biosimilars recommended for EU approval
12:03p NOVARTIS : beats 1Q profit forecasts
09:09aDJNOVARTIS : Profit Dented by Investment in New Drugs -- Update
07:40aDJNOVARTIS : 1Q Net Income Down 17%, Hurt by Drug Failure
07:01a NOVARTIS : delivered sales growth across all divisions (cc1) as growth drivers, ..
04/24 J&J, Takeda among interested in Brazil's Hypermarcas, sources say
04/24 AMGEN INC. (NASDAQ : AMGN) Files An 8-K Entry into a Material Definitive Agreeme..
04/24 NOVARTIS : expands global collaboration with Amgen to commercialize first-in-cla..
More news
Sector news : Pharmaceuticals - NEC
02:19p Eli Lilly's profit beats on demand for new drugs
02:14pDJELI LILLY AND : Working to Cut Costs
12:50p DuPont profit beats on strong seed demand
12:50p DuPont profit beats on strong seed demand
10:17a Fresenius picks up M&A pace with Akorn, Merck KGaA deals
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07:42a Novartis Q1 sales down 1%; non-GAAP EPS down 3%; shares ahead 2% premarket
06:58a WALL STREET BREAKFAST : Border Wall, Taxes And Tariffs
05:35a Novartis beats by $0.01, misses on revenue
04:42a NOVARTIS Q1 2017 : Mixed Signals For Investors
04:28a European earnings roundup
Advertisement
Financials ($)
Sales 2017 48 498 M
EBIT 2017 11 367 M
Net income 2017 7 543 M
Debt 2017 15 250 M
Yield 2017 3,80%
P/E ratio 2017 22,39
P/E ratio 2018 19,62
EV / Sales 2017 4,35x
EV / Sales 2018 4,14x
Capitalization 195 490 M
More Financials
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 31
Average target price 79,4 $
Spread / Average Target 6,7%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-1.08%195 490
JOHNSON & JOHNSON6.67%333 142
ROCHE HOLDING LTD.8.21%220 797
PFIZER INC.3.88%200 926
MERCK & CO., INC.5.55%170 359
SANOFI10.33%119 103
More Results